EOS Imaging Announces Corporate Agreement With The Schön Kliniken Hospital Network In Germany

PARIS--(BUSINESS WIRE)--EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, announced today a corporate agreement with the prestigious Schön Kliniken Hospital Network that could lead to the EOS platform becoming part of the standard of care for treating their orthopaedic patients. Two EOS units have already been acquired by sites within the Schön Klinik network earlier this year.

There are 17 Schön Kliniken hospitals in Germany, employing more than 9,400 people who treat more than 100,000 patients each year. It is one of the largest owner-managed clinic groups in the German market and specializes in orthopaedics (back, spine, bones and joints), neurology (brain and nerves) and pediatric care. Two EOS platforms were acquired earlier this year by the network, and the first will be installed in the Munich Harlaching Clinic. The network also expects to open a site in London, England, in the near future. The Schön Kliniken Corporate agreement is the first of its kind for EOS imaging in Germany, a market where the company just sold its 10th unit.

Carla Naumann, Member of the Board of Schön Kliniken, said, “We decided to invest in the EOS technology because we believe the accurate and holistic measurements of spine problems, especially scoliosis, will improve the clinical outcomes for our patients. The 3D models, automatically calculated clinical parameters, and new suite of 3D surgical planning solutions that EOS offers are all part of our shared vision for improving the treatment of our orthopaedic patients. Particularly for our young patients that often require regular imaging monitoring and follow up, we value the reduced radiation that EOS offers.”

Marie Meynadier, CEO of EOS imaging, commented, “We’re enthusiastic about the choice of the Schön Kliniken network to start adopting EOS as a standard of care. Their focus on value-based healthcare and enhancing medical outcomes via measurement is a strong endorsement of the value of our technology and contributes to our current growing momentum in the German market.”

For more information, please visit www.eos-imaging.com.

EOS imaging has been chosen to be included in the new EnterNext© PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.

EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI

About EOS imaging

EOS imaging designs, develops, and markets EOS^®, an innovative medical imaging system dedicated to osteoarticular pathologies and orthopedics, as well as associated solutions. The Company is authorized to market in 51 countries, including the United States, Japan, China, and the European Union. The Group posted 2015 revenues of €21.8 million and employs 122 people. The Group is based in Paris and has five subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada), Frankfurt (Germany) and Singapore.